Copyright
©The Author(s) 2024.
World J Diabetes. Nov 15, 2024; 15(11): 2264-2271
Published online Nov 15, 2024. doi: 10.4239/wjd.v15.i11.2264
Published online Nov 15, 2024. doi: 10.4239/wjd.v15.i11.2264
Mechanism of action | Description | Ref. |
miR-129-5p modulation | Bone marrow–derived mesenchymal stem cell–derived exosomes deliver miR-129-5p, which targets and downregulates HMGB1. This leads to reduced neuroinflammation and improved neurological outcomes | Wang et al[1], 2024 |
Attenuation of oxidative stress | Exosomes reduce oxidative stress by modulating the expression of antioxidant enzymes and by reducing the production of reactive oxygen species, thereby protecting neurons from damage | Gómez-de Frutos et al[2], 2024 |
Promotion of neurogenesis | Stem cell–derived exosomes promote neurogenesis by delivering growth factors and microRNAs that support the proliferation and differentiation of neural progenitor cells in the damaged brain | Cheng et al[4], 2024 |
Inhibition of apoptosis | Exosomes carry antiapoptotic signals, such as miRNAs and proteins, which inhibit the activation of apoptotic pathways in neurons, reducing cell death in the affected brain regions | Larsson et al[3], 2024 |
Reduction of blood–brain barrier disruption | Bone marrow–derived mesenchymal stem cell–derived exosomes strengthen the blood–brain barrier by enhancing tight junction protein expression and reducing vascular permeability, thus preventing further brain injury post-hemorrhage | Lv et al[5], 2024 |
Modulation of immune response | Exosomes modulate the immune response by altering the activity of microglia and macrophages, reducing the production of proinflammatory cytokines, and promoting a neuroprotective environment | Southerland et al[6], 2024 |
Enhancement of angiogenesis | Bone marrow–derived mesenchymal stem cell–derived exosomes promote angiogenesis by delivering proangiogenic factors such as VEGF, which support the formation of new blood vessels and improve blood supply to the injured brain tissue | Wang et al[1], 2024 |
Regulation of autophagy | Exosomes influence autophagy processes in neurons and glial cells, contributing to the clearance of damaged proteins and organelles and supporting cellular homeostasis and survival | Wang et al[1], 2024 |
miRNA-mediated gene expression modulation | Through the delivery of various miRNAs, exosomes modulate the expression of genes involved in inflammation, cell survival, and repair processes, facilitating recovery from brain injury | Gómez-de Frutos et al[2], 2024 |
Neuroprotection through anti-inflammatory effects | Bone marrow–derived mesenchymal stem cell–derived exosomes reduce the expression of proinflammatory genes and increase anti-inflammatory cytokines, protecting neural tissue from secondary damage post-hemorrhage | Cheng et al[4], 2024 |
Mechanism | Diabetic cerebral hemorrhage | Nondiabetic cerebral hemorrhage | Ref. |
miR-129-5p modulation | Regulates neuroinflammation: MiR-129-5p from bone marrow–derived mesenchymal stem cell–derived exosomes modulates neuroinflammation by targeting HMGB1, which reduces neurological impairment and oxidative stress | Modulates neuroinflammation and cellular stress: Similar pathways involving miR-129-5p can modulate inflammation and oxidative stress, but they are less studied in nondiabetic contexts | Wang et al[1], 2024; Gómez-de Frutos et al[2], 2024 |
HMGB1 targeting | Attenuates damage: Targeting HMGB1 with miR-129-5p-loaded exosomes can alleviate brain damage by reducing inflammatory responses and promoting cellular repair | Reduces inflammation and promotes recovery: Targeting HMGB1 may reduce inflammation and support recovery, but the specific mechanisms and efficacy may differ because of the absence of diabetes-related complications | Wang et al[1], 2024; Cheng et al[4], 2024 |
Impact on neurological outcomes | Improves outcomes significantly: Enhanced targeting of HMGB1 and reduction in neuroinflammation lead to more favorable recovery in diabetic cerebral hemorrhage models | Varied outcomes: The efficacy of HMGB1 targeting in nondiabetic hemorrhages can be variable, with outcomes influenced by the absence of diabetes-related factors | Gómez-de Frutos et al[2], 2024; Larsson et al[3], 2024 |
Mechanistic differences | Diabetes-specific effects: The presence of diabetes affects the baseline inflammatory state and cellular response, influencing how miR-129-5p and HMGB1 targeting modify outcomes | General mechanisms: In nondiabetic conditions, the effects of miR-129-5p and HMGB1 targeting are based on standard inflammatory pathways without additional diabetes-related complications | Lv Y et al[5], 2024; Southerland et al[6], 2024 |
Application/direction | Clinical application | Future directions | Ref. |
Exosome-based delivery of miR-129-5p | Targeted therapy: Exosomes derived from bone marrow mesenchymal stem cells loaded with miR-129-5p can target HMGB1, potentially attenuating neurological impairments in diabetic cerebral hemorrhage | Expand research: Investigate the effectiveness of miR-129-5p-loaded exosomes in broader diabetic and nondiabetic neurological conditions and optimize exosome delivery systems for enhanced therapeutic efficacy | Wang et al[1], 2024 |
Reduction of inflammation through exosomal cargo | Anti-inflammatory effects: Exosomes can deliver anti-inflammatory agents to mitigate neuroinflammation in diabetic cerebral hemorrhage | Explore mechanisms: Study the specific exosomal components responsible for reducing inflammation and their impacts on long-term outcomes in diabetic patients | Gómez-de Frutos et al[2], 2024 |
Exosome-mediated neuroprotection | Neuroprotective strategies: Utilizing exosomes to deliver neuroprotective agents can reduce oxidative stress and cell death in diabetic neurological complications | Develop neuroprotective formulations: Focus on formulating exosomes with neuroprotective agents and assessing their safety and efficacy in clinical trials | Cheng et al[4], 2024 |
Biomarker discovery and monitoring | Diagnostic tool: Exosomal microRNAs can serve as biomarkers for the early diagnosis and monitoring of disease progression in diabetic neurological disorders | Validate biomarkers: Conduct longitudinal studies to validate exosomal biomarkers and their predictive value for disease outcomes | Liao et al[8], 2023 |
Combination therapies | Synergistic approaches: Combining exosome-based therapies with other treatments, such as hyperglycemia management and lifestyle modifications, can enhance overall therapeutic efficacy | Integrate therapies: Explore synergistic effects of combining exosome-based therapies with traditional and novel treatments in clinical settings | Su et al[7], 2024 |
Personalized medicine | Tailored treatments: Personalized exosome-based therapies can be developed on the basis of individual patient profiles and specific disease mechanisms | Customize approaches: Research personalized exosome-based treatments tailored to the genetic and metabolic profiles of diabetic patients | Zeinhom et al[9], 2024 |
- Citation: Cheng CH, Hao WR, Cheng TH. Stem cell exosomes: New hope for recovery from diabetic brain hemorrhage. World J Diabetes 2024; 15(11): 2264-2271
- URL: https://www.wjgnet.com/1948-9358/full/v15/i11/2264.htm
- DOI: https://dx.doi.org/10.4239/wjd.v15.i11.2264